Figure 4

Percent of patients achieving lipid targets at 6 weeks (treated with high-potency statins^†at baseline). *Triple target = LDL-C <100 mg/dL and non-HDL-C <130 mg/dL and Apo B <90 mg/dL ^†High potency stratum included: simvastatin 40 mg, atorvastatin 20 mg, rosuvastatin 5 mg ^‡Ratio of the predictive odds of attaining target on EZ+Simva versus Rosuvastatin based on the logistic model (fitted within each subgroup) with terms for treatment and baseline values of the variable being modeled. Apo B = apolipoprotein B; E = ezetimibe; LDL-C = low-density lipoprotein cholesterol; non-HDL-C = non-high-density lipoprotein cholesterol; R = rosuvastatin; S = simvastatin